Alnylam Pharmaceuticals, Inc. $ALNY Stock: Candriam S.C.A. Reduces Stake

Candriam S.C.A. cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.4% in the 3rd quarter, Holdings Channel reports. The firm owned 306,933 shares of the biopharmaceutical company’s stock after selling 7,579 shares during the period. Candriam S.C.A.’s holdings in Alnylam Pharmaceuticals were worth $76,009,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ALNY. Toth Financial Advisory Corp acquired a new position in Alnylam Pharmaceuticals in the third quarter worth approximately $25,000. Keating Financial Advisory Services Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $42,000. Burkett Financial Services LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $37,000. CoreCap Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 744.4% during the 3rd quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 134 shares during the last quarter. Finally, Ascentis Independent Advisors bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter worth $64,000. 92.97% of the stock is currently owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares in the company, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $155.94 on Friday. The company’s fifty day moving average is $228.57 and its two-hundred day moving average is $281.10. Alnylam Pharmaceuticals, Inc. has a 52-week low of $154.30 and a 52-week high of $479.79. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.48 and a quick ratio of 2.43. The firm has a market capitalization of $20.89 billion, a price-to-earnings ratio of 8.10 and a beta of 0.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the prior year, the business earned $2.90 earnings per share. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ALNY shares. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 30th. Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 2nd. The Goldman Sachs Group lowered their target price on shares of Alnylam Pharmaceuticals from $536.00 to $320.00 and set a “buy” rating on the stock in a research report on Friday, October 30th. Citigroup cut their target price on Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Finally, Truist Financial cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and reduced their price target for the stock from $315.00 to $225.00 in a research report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $305.86.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach.

Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.